HAMP and anemia: Furthermore, IL-6 has been shown to directly contribute to adverse outcomes in CKD such as anemia by upregulating hepcidin production in hepatocytes and inducing cardiac remodeling in myocytes by activating the gp130/IL-6R complex, resulting in phosphorylation and activation of STAT3 [162,262,263,264].